Fre­quen­cy Ther­a­peu­tics re­ports tri­al fail and lays off over half of staff — stock cap­sizes

Fre­quen­cy Ther­a­peu­tics an­nounced Mon­day morn­ing that its lead can­di­date, a drug for hear­ing loss, failed a Phase IIb study. As a re­sult, the Lex­ing­ton, MA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.